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ZincConsidering that intracellular signaling pathways that modulate brain BDNF are implicated in antidepressant
responses, this study investigated whether signaling pathway inhibitors upstream to BDNF might inﬂuence the
antidepressant-like effect of zinc, a metal that has been shown to display antidepressant properties. To this
end, the inﬂuence of i.c.v. administration of H-89 (1 μg/site, PKA inhibitor), KN-62 (1 μg/site, CAMKII inhibitor),
chelerythrine (1 μg/site, PKC inhibitor), PD98059 (5 μg/site, MEK1/2 inhibitor), U0126 (5 μg/site, MEK1/2
inhibitor), LY294002 (10 nmol/site, PI3K inhibitor) on the reduction of immobility time in the tail suspension
test (TST) elicited by ZnCl2 (10 mg/kg, p.o.) was investigated. Moreover, the effect of the combination of sub-
effective doses of ZnCl2 (1 mg/kg, p.o.) and AR-A014418 (0.001 μg/site, GSK-3β inhibitor) was evaluated. The
occurrence of changes in CREB phosphorylation and BDNF immunocontent in the hippocampus and prefrontal
cortex of mice following ZnCl2 treatment was also investigated. The anti-immobility effect of ZnCl2 in the TST
was prevented by treatment with PKA, PKC, CAMKII, MEK1/2 or PI3K inhibitors. Furthermore, ZnCl2 in combina-
tion with AR-A014418 caused a synergistic anti-immobility effect in the TST. None of the treatments altered
locomotor activity of mice. ZnCl2 treatment caused no alteration in CREB phosphorylation and BDNF
immunocontent. The results extend literature data regarding the mechanisms underlying the antidepressant-
like action of zinc by indicating that its antidepressant-like effect may be dependent on the activation of PKA,
CAMKII, PKC, ERK, and PI3K/GSK-3β pathways. However, zinc is not able to acutely increase BDNF in the
hippocampus and prefrontal cortex.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Depression is a common, chronic and disabling psychiatric disorder,
resulting in a social and economic burden, besides enormous personal
suffering and increased mortality risk (Lepine and Briley, 2011).
Although there are several classes of antidepressants, the use of these
drugs is associated with several side effects (Bet et al., 2013), a delay
in symptomremission (Nemeroff andOwens, 2002) and a large number
of partial responses or lack of responses (Ruhe et al., 2011). Thesetor; CAMKII, Ca2+/calmodulin-
ement binding protein; ERK,
nthase kinase 3; H-89, N-[2-(p-
; i.c.v., intracerebroventricular;
xo-3-(4-phenyl-1-piperazinyl)
in kinase kinase; O.D., optical
inase A; PKC, protein kinase C;
a, Centro de Ciências Biológicas,
nópolis, SC, Brazil. Tel.: +55 48
.factors underscore the need to investigate alternative treatments or
prevention strategies for depression.
Zinc is one of the agents used in the augmentation therapies for the
treatment of depression (Lai et al., 2012; Swardfager et al., 2013;
Szewczyk et al., 2008) and the concentration of this element in the
blood can be used as a marker of depression (Siwek et al., 2013).
Serum zinc levels are reported to be decreased in depressed patients
(Maes et al., 1999, Maes et al.,1997; Siwek et al., 2010) and increased
after the treatment with antidepressants (Siwek et al., 2010). Notably,
serum zinc levels were correlated with the severity of depression
(Irmisch et al., 2010) and zinc supplementation improved the efﬁcacy
of antidepressants in patients that were resistant to drug therapy
(Siwek et al., 2009). Recently, zinc monotherapy was reported to
improvemood in overweight or obese subjectsmost likely by increasing
BDNF levels (Solati et al., 2014). Consistent with these data, it is well
established that zinc supplementation provides an antidepressant-like
effect in predictive tests for antidepressant activity (Brocardo et al.,
2007; Cunha et al., 2008; Franco et al., 2008; Kroczka et al., 2001;
Lobato et al., 2008; Nowak et al., 2003; Rosa et al., 2003; Sowa-Kucma
et al., 2008; Szewczyk et al., 2009) and zinc-deﬁcient diet leads to a
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Tamano et al., 2009; Tassabehji et al., 2008; Whittle et al., 2009).
Zinc has been reported to activatemetabotropic GPR39 (Besser et al.,
2009; Yasuda et al., 2007), a G protein-coupled receptor 39 that is
widely expressed in the central nervous system (Howard et al., 2001).
Of note, zinc-deﬁcient diet for six weeks is associated with a signiﬁcant
reduction in GPR39 receptor and brain-derived neurotrophic factor
(BDNF) protein expression in the frontal cortex of mice as well as a
depressive-like behavior (Mlyniec et al., 2013). Zinc-deﬁcient diet for
six weeks also decreased expression of CREB and BDNF in the hippo-
campus (Mlyniec et al., 2014). GPR39 expression was decreased in the
hippocampus and frontal cortex of zinc deﬁcient mice and rats as
well as in the hippocampus and cerebral cortex of suicide victims
(Mlyniec et al., 2014). Zinc deﬁcient diet for four or six weeks also
decreased p-CREB and BDNF levels in the hippocampus (Doboszewska
et al., 2015). On the other hand, chronic treatment with zinc induced
an increase in cortical BDNF mRNA level (Nowak et al., 2004).
Despite the devastating impact of depression, its pathophysiology
and etiology are not completely clariﬁed. The monoaminergic neuro-
transmitter system has received great attention in depression, and its
importance is conﬁrmed by the fact that effective antidepressant
drugs exert their primary biochemical effects by regulatingmonoamin-
ergic neurotransmission (Nemeroff and Owens, 2002). Although most
antidepressants increase the levels of monoamines acutely, clinical
response in humans occurs only after chronic treatment, suggesting
that the activation of cellular signaling pathways associated with
neuroplasticity and cellular survival are required for the effectiveness
of antidepressants. Consistent with this assumption, several preclinical
and clinical studies have shown that intracellular signaling pathways
are targets for the actions of antidepressant agents (Kitagishi et al.,
2012; Marsden, 2013).
BDNF is a neurotrophin downstream to several cellular signaling
pathways widely recognized as a key target implicated both in the
etiology of depression and in the antidepressant drug action (Castren
and Rantamaki, 2010; Duman and Monteggia, 2006). According to a
meta-analysis, depressive patients have a decrease in serumandplasma
BDNF levels (Bocchio-Chiavetto et al., 2010). On the other hand,
peripheral BDNF administration produces an antidepressant-like
behavior in mice (Schmidt and Duman, 2010). Likewise, a meta-
analysis showed that antidepressant treatment increased serum and
plasma BDNF levels in depressive patients (Brunoni et al., 2008).
Regarding brain BDNF levels following antidepressant treatments
in rodents, it is widely reported that chronic, but not acute adminis-
tration of these agents is associated with enhanced BDNF levels in
the hippocampus and prefrontal cortex (Balu et al., 2008; De
Foubert et al., 2004). Of note, the NMDA receptor antagonist keta-
mine administered acutely has been shown to increase BDNF levels
in the hippocampus and prefrontal cortex of rats and mice (Garcia
et al., 2008; Zhou et al., 2014). However, it remains to be established
if zinc, that is also an NMDA receptor antagonist, is able to acutely
produce such effect.
Many intracellular signal transduction cascades can inﬂuence,
directly or indirectly, the activation of cAMP response element binding
protein (CREB), which in turn is responsible for the expression of
BDNF. Some of the enzymes that participate in these cascades are
protein kinase A (PKA), protein kinase C (PKC), Ca2+/calmodulin-
dependent protein kinase (CAMKII), extracellular-regulated protein
kinase (ERK), phosphoinositide 3-kinase (PI3K), and glycogen
synthase kinase 3 (GSK-3) (Hashimoto et al., 2004; Malberg and
Blendy, 2005). Taking into account the importance of BDNF for
depression and that several studies have suggested that the
antidepressant-like effect of zinc may involve BDNF increase, this
study aimed at investigating whether selective inhibitors of signaling
enzymes (upstream to BDNF) might inﬂuence the antidepressant-like
effect of zinc and if, similarly to the result reported for ketamine, the
acute administration of zinc is able to increase brain BDNF levels.2. Materials and methods
2.1. Animals
Female Swiss mice (45–55 days old, weighing 30–45 g) were
maintained at 20–22 °C with free access to water and food, under a
12:12 h light:dark cycle (lights on at 7:00 a.m.). The animals were
caged in groups of 15 in a 41 × 34 × 16-cm cage. All behavioral tests
were carried out between 9:00 a.m. and 04:00 p.m. Animals were
acclimatized to the laboratory for at least 12 h before testing. The
animals were used according to the NIH Guide for the Care and Use of
Laboratory Animals and the experiments were performed after approv-
al of the protocol by the Ethics Committee of the Institution. All efforts
were made to minimize animal suffering and to reduce the number of
animals used in the experiments.
2.2. Drugs and treatment
The following drugswere used: zinc chloride (ZnCl2) (1 or 10mg/kg),
N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide —
H-89 (1 μg/site, PKA inhibitor), 4-[2-[(5-isoquinolinyl-sulfonyl)
methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl) propyl] phenyl ester
—KN-62 (1 μg/site, CAMKII inhibitor), chelerythrine (1 μg/site, PKC inhib-
itor), PD98059 (5 μg/site, inhibitor of mitogen-activated protein kinase
kinase (MAPKK/MEK 1/2)), U0126 (5 μg/site, inhibitor of MEK1/2),
LY294002 (10 nmol/site, PI3K inhibitor), AR-A014418 (0.001 μg/site,
selective GSK-3β inhibitor). All these drugs were obtained from Sigma-
Aldrich Chemical Co., St. Louis, USA. ZnCl2 was dissolved in distilled
water and administered orally (p.o.). H-89, KN-62, chelerythrine,
PD98059, U0126, LY294002, AR-A014418 were dissolved in saline
(0.9% NaCl) at a ﬁnal concentration of 1% dimethyl sulfoxide (DMSO)
and administered by intracerebroventricular (i.c.v.) route. The drugs
were freshly prepared before treatment and administered in a volume
of 10 ml/kg body weight (p.o. route) or 5 μl/site (i.c.v. route). Control
animals received the appropriate vehicle.
I.c.v. administration was performed as described previously (Kaster
et al., 2012). For injection, 26 G needle was attached to a polypropylene
cannula coupled to aHamiltonmicrosyringe 50 μl. Themicewere lightly
anesthetized with isoﬂurane (2.5%; Abbot Laboratórios do Brasil Ltda.,
Rio de Janeiro, RJ, Brazil) using a vaporizer system (SurgiVet Inc.,
Waukesha, WI, USA). The administration was performed by inserting
the needle perpendicularly through the skull and no more than 2 mm
into the brain of the mice. The injection was given over 30 s, and the
needle remained in place for another 30 s in order to avoid the reﬂux
of the substances injected. The injection site was 1 mm to the right or
left from the midpoint on a line drawn through to the anterior base of
the ears. The injections were performed by an experienced person,
and after dissection of the brain of the animal, the success of the
injection was examined, macroscopically, discarding animals whose
injection has been held in inappropriate place or has caused cerebral
hemorrhage (b5%).
To test the hypothesis that the antidepressant-like effect of zinc is
dependent on the activation of intracellular signaling pathways, mice
were pretreated with an effective dose of ZnCl2 (10 mg/kg, p.o.), and
30 min later they received sub-effective doses of either H-89, KN-62,
PD98059, U0126, chelerythrine or LY294002. The animals were submit-
ted to behavioral tests 30 min later (60 min after zinc administration).
Moreover, to investigate a possible synergistic effect between zinc and
GSK-3β inhibitor, animals received (p.o.) vehicle or a sub-effective
dose of ZnCl2 (1 mg/kg). After 30 min, they received (i.c.v.) a sub-
effective dose of AR-A014418 or vehicle. Thirty minutes after the end
of the last treatment, the behavioral tests were performed.
The doses of ZnCl2 usedwere chosen based on experiment previous-
ly performed in our laboratory (Cunha et al., 2008). The doses of H-89,
KN-62, chelerythrine, PD98059, U0126, LY294002, and AR-A014418
were chosen based on experiments previously performed in our
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Cunha et al., 2014; Moretti et al., 2014; Zeni et al., 2012). The number
of animals used for behavioral tests was 7–8 per group.
2.3. Behavioral tests
2.3.1. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Mice both acoustically and visually isolated were suspended 50 cm
above the ﬂoor by adhesive tape placed approximately 1 cm from the
tip of the tail. Mice were considered immobile only when they hung
passively and completely motionless. The immobility time was record-
ed during a 6-min period by an experienced observer. A decreased
immobility time was considered indicative of an antidepressant-like
effect (Steru et al., 1985).
2.3.2. Open-ﬁeld test
In order to exclude the possibility that the alteration in the immobil-
ity time in the TST is due to interference of locomotor activity, the
animals were subjected to an open-ﬁeld test for 6 min, as described by
Moretti et al. (2014). This test was conducted in a wooden box
measuring 40 × 60 × 50 cm, with the ﬂoor of the arena divided into
12 equal squares. At the start of each trial a mouse was placed in the
left corner of the ﬁeld and was allowed to freely explore the arena.
The number of squares crossed with all four paws (crossings) was
manually counted and was the parameter used to indicate locomotor
activity. The apparatus was cleaned with a solution of 10% ethanol
between tests in order to hide animal clues. The test was carried out
in a temperature and light controlled room.
2.4. Biochemical analysis
Independent groups of mice (n= 4–8 per group) were used to bio-
chemical analysis. Animals received (p.o.) vehicle or ZnCl2 (10 mg/kg).
After 60 min, animals were decapitated for biochemical analysis.
2.4.1. Tissue preparation
After decapitation, the brain of each animal was removed and the
hippocampus and the prefrontal cortex were quickly dissected (4 °C),
placed in liquid nitrogen and stored at−80 °C until use. The samples
were prepared as described previously (Oliveira et al., 2008). Brieﬂy,
tissues were mechanically homogenized in TRIS 50 mM pH 7.0, EDTA
1 mM, NaF 100 mM, PMSF 0.1 mM, Na3VO4 2 mM, Triton X-100 1%,
glycerol 10%, and Amresco Protease Inhibitor Cocktail catalog number
M222 (Working concentration: AEBSF 0.50 mM, Aprotinin 0.30 μM,
Bestatin 10.00 μM, E-64 10.00 μM, Leupeptin 10.00 μM, EDTA
50.00 μM). Lysates were centrifuged (10.000 ×g for 10 min, at 4 °C) to
eliminate cellular debris. The supernatants were diluted 1/1 (v/v)
in TRIS 100 mM pH 6.8, EDTA 4 mM, SDS 8% and boiled for
5 min. Thereafter, samples were diluted (40% glicerol, 100 mM
TRIS, bromophenol blue, pH 6.8) in the ratio 25:100 (v/v) and
β-mercaptoethanol (ﬁnal concentration 8%) was added on the samples.
Protein content was calculated using a standard curve with bovine
serum albumin as standard (Peterson, 1977).
2.4.2. Western blotting
The same amount of protein (60 μg per lane) for each sample was
electrophoresed in SDS–PAGE minigels (10% acrylamide) and trans-
ferred to nitrocellulosemembranes using a semi-dry blotting apparatus
(1.2 mA/cm2; 1.5 h). To verify transfer efﬁciency process, membranes
were stained with Ponceau Stain. After this process, the resulting
membranes were incubated in a blocking solution (5% non-fat dry
milk in TRIS-buffered saline (TBS)) for 60 min at room temperature,
and were subsequently probed via incubation with anti-phospho-
CREB (Ser133) anti-CREB (Cell Signaling, 1:1000) and anti-BDNF(Santa Cruz, 1:1000). All of the probes were diluted in a TBS solution
that contained 0.1% Tween 20 (TBS-T). Next, themembraneswere incu-
bated with an anti-rabbit horseradish peroxidase (HRP)-conjugated
secondary antibody (Millipore 1:5.000) for 60 min, and the immu-
noreactive bands were developed using a chemiluminescence kit
(LumiGLOH, Cell Signaling, Beverly, MA, USA). All blocking and incuba-
tion steps were followed by three washes (5 min) of the membranes
with TBS-T. To ascertain whether the protein load for each of the
experimental groupswas the same, the expression level of a housekeep-
ing protein, β-actin, was evaluated using a mouse anti-β-actin primary
antibody (Santa Cruz, 1:2000) and an anti-mouse HRP-conjugated
(Millipore 1:4000) secondary antibody.
The optical density (O.D.) of the bands was quantiﬁed using Scion
ImageTM (Frederick, MD, USA). The phosphorylation levels of CREB
were determined as a ratio of the O.D. of the phosphorylated band
over the O.D. of the total band. The BDNF immunocontent was
determined from the relationship between the O.D. of the BDNF band
and the O.D. of the β-actin band. Data were expressed as percentage
of the control (considered as 100%).
2.5. Statistical analysis
The Kolmogorov–Smirnov test was used to evaluate the normality
assumption of behavioral and biochemical data. All variables in the
present study showed a normal distribution. Differences among
experimental groups were determined by two-way ANOVA followed by
Newman–Keuls post hoc test (behavioral analysis) or Student's t-test
(immunoblotting analysis) when appropriate. A value of p b 0.05 was
considered to be statistically signiﬁcant. All data are presented as
mean + standard error of the mean (S.E.M).
3. Results
3.1. Behavioral observations
To evaluate the inﬂuence of treatment of mice with inhibitors of
signaling pathways in the antidepressant-like behavior elicited by
ZnCl2, the immobility time of mice in the TST was measured (Figs. 1A,
C, E, 2A, C, 3A, C). In order to rule out the possibility that the alterations
in the immobility time in the TST were due to interference of the
locomotor activity, the number of crossings was measured (Fig. 1B, D,
F, 2B, D, 3B, D).
The results presented in Fig. 1A show the anti-immobility effect
of ZnCl2 (10 mg/kg, p.o.) (p b 0.01) was completely prevented by
treatment of animals with the PKA inhibitor H-89 (1 μg/site, i.c.v.).
The two-way ANOVA revealed a signiﬁcantly main effect of H-89
treatment [F (1,28) = 4.38, p b 0.05], ZnCl2 treatment [F (1,28) =
8.32, p b 0.01] and H-89 × ZnCl2 treatment interaction [F (1,28) =
4.71, p b 0.05] to immobility time. Post hoc analysis indicated the
treatmentwith H-89 blocked the decrease in immobility time produced
by ZnCl2 in the TST. Fig. 1B shows the administration of H-89 alone or in
combination with ZnCl2 was devoid of effect in the open-ﬁeld test.
The two-way ANOVA revealed no signiﬁcantly effect of H-89 treatment
[F (1,28) = 0.28, p N 0.05], ZnCl2 treatment [F (1,28) = 0.29, p N 0.05]
and H-89 × ZnCl2 treatment interaction [F (1,28) = 2.29, p N 0.05] to
number of crossings.
As presented in Fig. 1C, the antidepressant-like behavior of ZnCl2
(10mg/kg, p.o.) (p b 0.01) was prevented by CAMKII inhibitor KN-62
(1 μg/site, i.c.v.). The two-way ANOVA revealed a signiﬁcantly main
effect of KN-62 treatment [F (1,28) = 27.47, p b 0.01], no main effect
of ZnCl2 treatment [F (1,28) = 0.84, p N 0.05] and a signiﬁcant effect
of KN-62 × ZnCl2 treatment interaction [F (1,28) = 22.57, p b 0.01] to
immobility time. As revealed by the post-hoc analysis, the anti-
immobility effect of ZnCl2 was completely prevented by treatment of an-
imals with KN-62. No effect in locomotor activity in the open-ﬁeld test
was observed (Fig. 1D): (KN-62 treatment [F (1,24) = 1.97, p N 0.05],
Fig. 1. Inﬂuence of PKA, CAMKII or PKC inhibition on the effects of ZnCl2 in the TST and open-ﬁeld test. Panels A and B: Effect of treatmentwith ZnCl2 (10mg/kg, p.o.) and/orH-89 (1 μg/site;
i.c.v.) on the immobility time in the TST (panel A) and on number of crossings in the open-ﬁeld test (panel B). Panels C and D: Effect of treatmentwith ZnCl2 (10mg/kg, p.o.) and/or KN-62
(1 μg/site; i.c.v.) on the immobility time in the TST (panel C) and on number of crossings in the open-ﬁeld test (panel D). Panels E and F: Effect of treatmentwith ZnCl2 (10mg/kg, p.o.) and/
or chelerythrine (1 μg/site; i.c.v.) on the immobility time in the TST (panel E) and on number of crossings in the open-ﬁeld test (panel F). Bars represent means + S.E.M. (n = 7–8).
**p b 0.01 compared with control (H2O + Vehicle). ##p b 0.01 compared with the group treated with ZnCl2 + Vehicle (two-way ANOVA followed by Newman–Keuls post hoc test).
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interaction [F (1,24) = 0.61, p N 0.05]).
Fig. 1E shows the inﬂuence of treatment of mice with PKC inhibitor
chelerythrine (1 μg/site, i.c.v.) on the anti-immobility effect of ZnCl2Fig. 2. Inﬂuence ofMEK1/2 inhibitionon the effects of ZnCl2 in the TST andopen-ﬁeld test. Panels A
immobility time in the TST (panel A) andonnumber of crossings in the open-ﬁeld test (panel B). Pa
the immobility time in theTST (panel C) andonnumberof crossings in the open-ﬁeld test (panelD)
##p b 0.01 compared with the group treated with ZnCl2 + Vehicle (two-way ANOVA followed b(10 mg/kg, p.o.) in the TST. Chelerythrine was able to abolish the
antidepressant-like behavior of ZnCl2. The two-way ANOVA revealed a
signiﬁcantly main effect of chelerythrine treatment [F (1,28) = 10.58,
p b 0.01], ZnCl2 treatment [F (1,28) = 8.99, p b 0.01] andandB: Effect of treatmentwith ZnCl2 (10mg/kg, p.o.) and/or PD98059 (5 μg/site; i.c.v.) on the
nels C andD: Effect of treatmentwith ZnCl2 (10mg/kg, p.o.) and/orU0126 (5 μg/site; i.c.v.) on
. Bars representmeans+S.E.M. (n=7–8). *pb 0.05 comparedwith control (H2O+Vehicle).
y Newman–Keuls post hoc test).
Fig. 3. Inﬂuence of PI3K/GSK-3βmodulation on the effects of ZnCl2 in the TST and open-ﬁeld test. Panels A and B: Effect of treatment with ZnCl2 (10 mg/kg, p.o.) and/or LY294002 (10
nmol/site; i.c.v.) on the immobility time in the TST (panel A) and on number of crossings in the open-ﬁeld test (panel B). Panels C and D: Effect of treatment with sub-effectives doses
of ZnCl2 (1 mg/kg, p.o.) and/or AR-A014418 (0.001 μg/site; i.c.v.) on the immobility time in the TST (panel C) and on number of crossings in the open-ﬁeld test (panel D). Bars represent
means+S.E.M. (n=7–8). **p b 0.01 comparedwith control (H2O+Vehicle). ##pb 0.01 comparedwith the group treatedwith ZnCl2+Vehicle (two-wayANOVA followed byNewman–
Keuls post hoc test).
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to immobility time. Post-hoc analyses indicated the treatment with
the PKC inhibitor chelerythrine blocked the decrease in immobility
time produced by ZnCl2 in the TST. No effect in locomotor activity in
the open-ﬁeld test was observed (Fig. 1F). The two-way ANOVA re-
vealed no signiﬁcant effect of chelerythrine treatment [F (1,28) =
0.48, p N 0.05], ZnCl2 treatment [F (1,28) = 0.00, p N 0.05] and
chelerythrine × ZnCl2 treatment interaction [F (1,28) = 3.51,
p N 0.05] to number of crossings.
Fig. 2A shows the inﬂuence of treatment of mice with MEK1/2
inhibitor PD98059 (5 μg/site, i.c.v.) on the antidepressant-like behavior
elicited by ZnCl2. The two-wayANOVA revealed a signiﬁcant differences
for PD98059 treatment [F (1,28) = 4.91, p b 0.05], ZnCl2 treatment
[F (1,28) = 6.22, p b 0.05], and PD98059 × ZnCl2 treatment interac-
tion [F (1,28) = 4.24, p b 0.05]. Post hoc analyses indicated that
ZnCl2 (10 mg/kg, p.o.) decreased the immobility time in the TST
(p b 0.01), an effect prevented by treatment of mice with PD98059.
None of the treatments caused changes in locomotor activity in the
open-ﬁeld test (Fig. 2B): (PD98059 treatment [F (1,28) = 0.34,
p N 0.05], ZnCl2 treatment [F (1,28) = 1.11, p N 0.05], and
PD98059 × ZnCl2 treatment interaction [F (1,28) = 0.02, p N 0.05]).
Similarly, treatment with the MEK1/2 inhibitor U0126 (5 μg/site,
i.c.v.) prevented the antidepressant-like effect elicited by ZnCl2
(Fig. 2C): (U0126 treatment [F (1,28)= 4.03, p N 0.05], ZnCl2 treatment
[F (1,28) = 6.08, p b 0.05], and U0126 × ZnCl2 treatment interaction
[F (1,28) = 4.65, p b 0.05]). As revealed by the post-hoc analysis, the
treatment with U0126 completely abolished the anti-immobility effect
of ZnCl2. None of the treatments caused changes in locomotor activity
in the open-ﬁeld test (Fig. 2D): (U0126 treatment [F (1,24) = 0.02,
p N 0.05], ZnCl2 treatment [F (1,24) = 3.97, p N 0.05], and
U0126 × ZnCl2 treatment interaction [F (1,24) = 0.46, p N 0.05]).
The results depicted in Fig. 3A show that the antidepressant-like
behavior elicited by ZnCl2 is inﬂuenced by the treatment with the
PI3K inhibitor LY294002 (10 nmol/site, i.c.v.). The two-way ANOVA re-
vealed signiﬁcant differences for LY294002 treatment [F (1,28)=10.63,
p b 0.01], ZnCl2 treatment [F (1,28) = 6.49, p b 0.05] and
LY294002 × ZnCl2 treatment interaction [F (1,28) = 5.15, p b 0.05].
Post hoc analyses indicated that ZnCl2 (10 mg/kg, p.o.) decreased the
immobility time (p b 0.01) and that this effect was prevented by
LY294002. None of the treatments caused changes in locomotor activity(Fig. 3B): (LY294002 treatment [F (1,25) = 3.89, p N 0.05], ZnCl2
reatment [F (1,25) = 1.59, p N 0.05], and LY294002 × ZnCl2 treatment
interaction [F(1,25) = 2.05, p N 0.05]).
Fig. 3C shows the administration of a sub-effective dose of ZnCl2
(1 mg/kg, p.o.) in combination with a sub-effective dose of the
GSK-3β inhibitor AR-A014418 (0.001 μg/site, i.c.v.) produced a
synergistic anti-immobility effect in the TST (p b 0.05):
(AR-A014418 treatment [F (1,26) = 0.81, p N 0.05], ZnCl2 treatment
[F (1,26) = 6.70, p b 0.05] and AR- A014418 ZnCl2 treatment inter-
action [F (1,26) = 4.84, p b 0.05]). As revealed by post-hoc analysis,
AR-A014418, administered at a dose that per se produced no signiﬁ-
cant effect in the TST, produced a synergistic effect in the TST when
combined with a sub-effective dose of ZnCl2. Fig. 3D shows that
this effect is not due to a psychostimulant effect, since the adminis-
tration of ZnCl2 alone or in combination with AR-A014418 did not
affect the locomotion ofmice in the open-ﬁeld test: (AR-A014418 treat-
ment [F (1,26) = 0.51, p N 0.05], ZnCl2 treatment [F (1,26) = 0.11,
p N 0.05], and AR-A014418 × ZnCl2 treatment interaction [F (1,26) =
1.74, p N 0.05]).
3.2. CREB phosphorylation and BDNF immunocontent
Fig. 4 shows a representativeWestern blot of the CREB phosphoryla-
tion in the hippocampus and prefrontal cortex (panels A and B,
respectively) and BDNF immunocontent in the hippocampus and
prefrontal cortex (panels C and D, respectively) of mice treated with
ZnCl2 (10mg/kg). Densitometric analysis revealed that CREB phosphor-
ylation was not affected in the hippocampus and prefrontal cortex
(panels A and B, respectively) (hippocampus [t(12) = −0.14,
p N 0.05], prefrontal cortex [t(12) = 0.19, p N 0.05]) (Student's t-test).
Similarly, no alteration in BDNF immunocontent in the hippocampus
or prefrontal cortex (panels C and D, respectively) (hippocampus
[t(12) = 0.41, p N 0.05], prefrontal cortex [t(6) = 0.60, p N 0.05]) was
observed in any experimental group (Student's t-test).
4. Discussion
In the present study we showed that the administration of the
inhibitors of several kinases, namely, PKA inhibitor H-89, CAMKII
inhibitor KN-62, MEK1/2 inhibitors PD98059 and U0126, PKC
Fig. 4. CREB phosphorylation and BDNF immunocontent in the hippocampus and prefrontal cortex 60min after ZnCl2 (10 mg/kg, p.o.) administration. Panels A and B: Effect of treatment
with ZnCl2 (10mg/kg, p.o.) in the CREB phosphorylation in hippocampus (panel A) and prefrontal cortex (panel B). A representative image and a quantitative analysis normalized to the
total-CREB band are shown. The level of CREB phosphorylation determined as a ratio of O.D. of the phosphorylated band over the O.D. of the total band is expressed as percentage of the
control (mean + S.E.M. of 7–8 mice; Student's t-test). Panels C and D: Effect of treatment with ZnCl2 (10 mg/kg, p.o.) on BDNF immunocontent in the hippocampus (panel C) and
prefrontal cortex (panel D). A representative image and a quantitative analysis normalized to the β-actin band are shown. The results are expressed as percentage of the control
(mean + S.E.M. of 4–8 mice; Student's t-test).
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antidepressant-like effect of ZnCl2 in TST. In addition, co-administration
of sub-effective doses of ZnCl2 and GSK-3β inhibitor AR-A014418
elicited a synergistic effect in the TST. However, CREB phosphorylation
and BDNF immunocontent were not altered in the hippocampus
and prefrontal cortex 60 min after the administration of ZnCl2 to
mice.
A great deal of effort has been spent in the search of adjuvant
therapies that may help to treat depression. One of the nutrients that
have received special attention in this regard is zinc. It has many
important functions to the organism, since more than 300 enzymes
have been identiﬁed as being dependent of this metal ion (McCall
et al., 2000) and approximately 2000 transcription factors require zinc
for the expression of their genes (Prasad, 2012). It is noteworthy that
zinc may interfere with intracellular signaling cascades. Some proteins
that can be modulated by zinc are: CAMKII (Lengyel et al., 2000), PKC
(Beyersmann and Haase, 2001), GSK-3 (Ilouz et al., 2002; Lee et al.,
2009), Akt (Lee et al., 2009; Liang et al., 2012), ERK (Franco et al.,
2008; Park et al., 2002), PI3K (Liang et al., 2012), and BDNF (Franco
et al., 2008; Mlyniec et al., 2013). However, most of these actions were
studied in peripheral tissues, whereas the zinc effects in the signaling
pathways in the brain remain to be established.Zinc is widely distributed in the central nervous system, being
abundant in the neocortex, striatum, hippocampus, and amygdala
(Paoletti et al., 2009). In the brain, zinc in its ionic form (Zn2+) is
highly enriched at many glutamatergic nerve terminals and is crucial
for neuronal activity (Sensi et al., 2009). The role of zinc in depres-
sion has been extensively studied and there are several reviews
about this subject (Lai et al., 2012; Nowak et al., 2005; Szewczyk
et al., 2010; Szewczyk et al., 2008). In addition to the fact that
serum zinc levels are signiﬁcantly lower in depressed people, there
is a gradual increase in its serum concentration after antidepressant
treatment (Siwek et al., 2010). Likewise, low dietary zinc intake is as-
sociated with a greater incidence of depression in both men and
women in two Australian cohorts (Vashum et al., 2014). On the
other hand, the supplementation with zinc reduces depression
scores and facilitates the treatment outcome in antidepressant treat-
ment resistant patients (Siwek et al., 2009). Along with this concep-
tual framework, preclinical studies corroborate the notion that zinc
exhibits antidepressant property by showing that this metal ion
produces antidepressant-like effects in several animal models of
depression (Cunha et al., 2008; Nowak et al., 2003; Sowa-Kucma
et al., 2008) and elicits a synergistic effect with antidepressants
(Cunha et al., 2008).
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involve interactionwith the serotonergic system (Szewczyk et al., 2009)
and inhibition of NMDA receptors (Rosa et al., 2003). It was also
established that zinc may interact with GPR39 (Mlyniec et al., 2013), a
vertebrate G protein-coupled receptor that when activated, may
stimulate PKA, PKC, CAMK and MAPK (Popovics and Stewart, 2011).
Thus, activation of the GPR39 receptor culminates in the activation of
CREB (Holst et al., 2004) with the consequent BDNF increase (Alboni
et al., 2011). It was shown that mice receiving a zinc deﬁcient diet for
6 weeks had signiﬁcant reduction in GPR39 (by 53%) and BDNF (by
49%) protein expression in the frontal cortex (Mlyniec et al., 2013).
However, the overall understanding of the intracellular mechanisms
underlying the antidepressant effect of zinc requires further studies.
Antidepressant responses have been attributed to the need of activa-
tion or inhibition of intracellular signal transduction cascades (Niciu
et al., 2013). Therefore, this study sought to investigate if inhibition of
signaling pathways upstream to BDNF and related to neuroplasticity,
neurogenesis and cell survival could inﬂuence the antidepressant-like
effect of zinc in the TST.
Stimulation of several G-coupled receptors can activate adenylyl
cyclase, which in turn converts ATP into cAMP. The enhanced PKA
activity as a consequence of this event has been reported to be implicat-
ed in the antidepressant responses of several agents (Almeida et al.,
2006; Liu et al., 2012; Niciu et al., 2013), and in hippocampal
neurogenesis induced by antidepressants (Anacker et al., 2011). In line
with this notion, a reduced PKA activity was found in the ﬁbroblasts of
melancholic depressive patients (Shelton et al., 1999). Of note, our
results show that the antidepressant-like effect of ZnCl2 in the TST is
dependent on the cellular signaling modulated by PKA, since the anti-
immobility effect of this metal ion was not observed in mice treated
with H-89. PKA activation was also shown to be implicated in some pe-
ripheral actions of zinc (Haase and Rink, 2009; von Bulow et al., 2007).
The role of CAMKII in regulating various forms of neuroplasticity and
in the pathophysiology and treatment of mood disorders has been
reported (Duet al., 2004). Long-term treatmentwith selective serotonin
reuptake inhibitors was shown to increase autophosphorylation and
activity of CAMKII (Tiraboschi et al., 2004). In agreement, CAMKII
inhibitor prevented the behavioral effects of several antidepressant
compounds in mice (Almeida et al., 2006; Cunha et al., 2014). Our
data demonstrated that the antidepressant-like effect of ZnCl2 was
prevented by treatment with KN-62, suggesting that its effect in the
TST is dependent on CaMKII pathway activation. This result is some-
what in agreement with a study which shows that zinc can activate
CaMK-II at relatively low concentration in vitro (Lengyel et al., 2000),
and is the ﬁrst to show that this pathway is involved in the behavioral
response of Zn in the TST.
All PKC isozymes are highly expressed in the central nervous system,
mainly in brain regions involved inmood regulation (Abrial et al., 2011).
Some studies showed that prefrontal cortex post-mortem tissue
samples from suicide victims with a history of a diagnosis of depression
had a decreased activity of PKC (Pandey et al., 2004). In agreement with
these data, PKC activation has been associated with antidepressant-like
behaviors (Zeni et al., 2012). In our study the antidepressant-like effect
of zinc was abolished by the administration of PKC inhibitor
chelerythrine, suggesting that the activation of PKC-mediated signaling
pathway is involved in zinc antidepressant-like effects, somewhat in
line with the fact that zinc may activate PKC in peripheral tissues
(Csermely et al., 1988; Haase and Rink, 2009).
Mitogen-activated protein kinases (MAPK) are important signal
transducing enzymes that are involved in many cellular processes,
including regulation of gene expression in response to extracellular
stimuli, cell proliferation, cell survival and death, besides its ability to
modulate the response to chemical and physical stresses (Chang and
Karin, 2001). Literature shows that inhibition of MAPK-ERK kinase
(MEK; the kinase upstream to ERK1/2) induces a depressive-like effect
and prevents the action of some antidepressants in mice (Dumanet al., 2007; Reus et al., 2014). Furthermore, corticosterone-induced
depressive-like behaviors in mice are associated with a reduction on
ERK1/2 phosphorylation (Gourley et al., 2008). In postmortem tissue
of humans with depression an increased expression of MAPK
phosphatase-1 (MKP-1), a negative regulator of MAPK was shown
(Duric et al., 2010). Our results provide evidence that the activation of
MEK/ERK pathway is implicated in the acute antidepressant-like effect
of ZnCl2, considering that the anti-immobility of ZnCl2 in the TST was
abolished either by PD98059 or U0126. A modulation of this signaling
pathway by zinc was also reported by other studies: a) zinc sulfate
increased ERK1/2 in neuroblastoma cells (An et al., 2005); b) chronic
treatment with ZnCl2 produced an increase in ERK phosphorylation in
the cerebral cortex of rats (Franco et al., 2008); c) ERK phosphorylation
increasedwith zinc supplementation and decreasedwhen synaptic zinc
was eliminated (Besser et al., 2009; Sindreu et al., 2011); d) zinc has
been shown to transactivate TrkB receptors causing Akt and ERK1/2
activation (Huang and McNamara, 2010).
The activation of PI3K, which catalyzes the production of
phosphatidylinositol-3,4,5-trisphosphate, induces Akt activation
(Cantley, 2002). The PI3K/Akt pathway has been shown to modulate
several signaling pathways, including GSK-3β. Regarding this enzyme, it
is well established that Akt leads to its phosphorylation (Ser9 residue),
with its consequent inactivation (Beaulieu et al., 2009). Abnormalities in
PI3K/Akt/GSK-3β pathway are implicated in depressive disorders. It
has been demonstrated that the prefrontal cortex and hippocampus
of suicide subjects with depression have a decreased activation of
PI3K (Dwivedi et al., 2008). Furthermore, inhibition of GSK-3β
has been reported to be associated with antidepressant effects
(Beaulieu et al., 2008; Rosa et al., 2008) and GSK-3β inhibitors
were reported to enhance the antidepressant-like effect of some an-
tidepressant compounds (Budni et al., 2011; Moretti et al., 2014).
Two sets of results obtained herein reinforce the notion that this
pathway plays an essential role in mood modulation: a) the reversal
of the anti-immobility effect of zinc by the PI3K inhibitor LY294002,
and b) the anti-immobility effect observed in the TST when sub-
effective doses of ZnCl2 and AR-A014418 were combined. These
data indicate that the antidepressant-like effect of ZnCl2 involves
the activation of PI3K/Akt and inhibition of GSK-3β. Indeed, our re-
sults are in line with other studies which show that some of the pe-
ripheral actions of zinc may be mediated via PI3K/Akt activation
(Lee et al., 2009; Liang et al., 2012), and GSK-3β inactivation
(Chanoit et al., 2008; Ilouz et al., 2002; Lee et al., 2009).
The activation of PKA, PKC, CaMKII or MAPK can lead to phosphory-
lation and subsequent activation of CREB (Hashimoto et al., 2004).
Furthermore, activation of the PI3K/Akt inhibits GSK-3β, preventing
the inhibitory effect of GSK-3β on CREB, thereby contributing to CREB
activation. Altogether, the results presented herein ﬁrstly indicate that
the antidepressant-like action of zinc in the TST is dependent on PKA,
PKC, CAMKII, ERK, PI3K/Akt/GSK-3β, which are signaling pathways
that converge to CREB activation and subsequent BDNF increase. This
notion is in agreement with literature results which show that zinc
deﬁciency leads to a decrease on BDNF levels in the frontal cortex
(Mlyniec et al., 2013) and that treatment with zinc hydroaspartate for
16 days prevented the chronic unpredictable stress-induced reduction
in BDNF mRNA levels in the hippocampus of rats (Cieslik et al., 2011).
It is worth mentioning that in spite of the fact that the behavioral
studies indicate that signaling pathways upstream to BDNF are involved
in the antidepressant-like effect of zinc in the TST, this study did not ﬁnd
any alteration in CREB phosphorylation and in the BDNF immunocontent
in the hippocampus and prefrontal cortex of mice treated acutely with
ZnCl2. In line with our results, an acute administration of conventional
antidepressants is reported to cause no alteration on hippocampal and/
or cerebrocortical BDNF levels (Balu et al., 2008). Conversely, chronic
treatment with zinc, similar to conventional antidepressants, (Balu
et al., 2008; De Foubert et al., 2004) was reported to increase BDNF
mRNA and protein levels in the hippocampus (Cieslik et al., 2011;
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Interestingly, clinical studies also report that while zinc monotherapy
(30 mg for 12 weeks) increased serum BDNF levels and decreased de-
pressive symptoms in overweight or obese subjects (Solati et al., 2014),
zinc supplementation (25mg for 12 weeks) combinedwith selective se-
rotonin reuptake inhibitor antidepressants reduced depressive symp-
toms, but did not change plasma levels of BDNF (Ranjbar et al., 2014).
On the other hand, the acute administration of ketamine, an NMDA
receptor antagonist that exerts rapid antidepressant effects, caused an
increase (60 min) in BDNF levels in the hippocampus and prefrontal
cortex of rats (Garcia et al., 2008; Zhou et al., 2014). In spite of the ability
of Zn to act as an NMDA receptor antagonist, its acute administration
was not able to cause CREB activation and to enhance BDNF content in
these brain structures, as opposed to ketamine. However, we could
not rule out that biochemical alterations in these parameters may
occur in another time point or in hippocampal or prefrontal cortex
sub-regions or even in different cell types of the central nervous system.
It is important to mention that Western blotting is not able to
discriminate cell types and sub-regions that may be particularly
involved in the antidepressant effect. Therefore, future studies using
additional approaches such as immunohistochemistry may allow
addressing this issue.
5. Conclusions
The present study signiﬁcantly extends literature data regarding the
mechanisms underlying the antidepressant-like action of zinc by
investigating the role of cellular signaling pathways implicated with
neuroplasticity, neurogenesis and cell survival in its effect in the TST.
Our data clearly indicate that its anti-immobility effect in the TST may
be dependent on the activation of PKA, CAMKII, ERK, PKC and PI3K/Akt
pathways, and inhibition of GSK-3β signaling pathways.
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